

Biobetter Market - Forecasts from 2019 to 2024

<https://marketpublishers.com/r/B5BD3EE26B6AEN.html>

Date: December 2019

Pages: 120

Price: US\$ 3,200.00 (Single User License)

ID: B5BD3EE26B6AEN

Abstracts

The global biobetter market is projected to grow at a CAGR of 30.64% to reach US\$64.041 billion by 2024, from US\$12.884 billion in 2018. The low development cost of biobetters as compared to the biologics will augment the market growth during the given forecast period.

Biobetters are improved versions of originator biologics which are similar to existing biologics entities by action, potency and by other factors. Biobetters are formed as a result of chemical modification, protein fusion, altered amino acid sequence, or humanization of the glycosylation pattern, which aims for the same target as the original biological, but has its effect longer period of time, typically at lower doses and with fewer side effects. Biobetters differ from biosimilars in that they are not identical to the original product and have been designed to have some advantage. Biobetters are handled exactly as innovator molecules in the United States, and similar regulatory standards are expected elsewhere. They are new molecular entities and will be subject to the standards applied to all new drugs

A biosimilar has no clinically meaningful differences in terms of safety and effectiveness from its reference product. In contrast, a biobetter can be thought of as an improved version of an existing biological product. There may be a change in structure that makes it safer or more effective or a change in the formulation that makes it easier to administer. A biobetter may have an easier clinical road since it benefits from prior knowledge of clinically effective targets/pathways. Biobetters allows companies to target an established mechanism, safety, and efficacy profile but gain the benefit of the patent protection and sales of a new molecular entity with significantly higher chances of successful registration.

The market is expected to show modest growth during the forecast period due to major manufacturers investing in the development of the biobetters in the face of impending

biosimilar competition. The low development cost of biobetters as compared to the biologics will also augment the market growth during the given forecast period. Moreover, many blockbuster biologics are going off-patent by 2023, providing ample opportunities for the companies to develop biobetter, thus, positively impacting the market. However, lack of awareness among the patient population in regards to the betters will restrain the growth of the global biobetter market during the given forecast period.

By Type

By type, the global biobetter market is segmented as monoclonal antibodies, vaccines, recombinant proteins, and others. Monoclonal antibodies are expected to hold a significant share which may be attributed to the favorable regulatory policies, and high adoption rate of therapeutic antibodies in emerging economies.

By Geography

Geographically, the global biobetter market is segmented as North America, South America, Europe, Middle East and Africa, and Asia Pacific. The Europe is expected to hold a significant share which may be attributed to the well-defined approval guidelines and the number of researches going in the region for the biobetter development.

Segmentation

The global biobetter market has been segmented by type, application, end-user, and geography.

By Type

Monoclonal Antibodies

Vaccines

Recombinant Proteins

Others

By Application

Oncology

Neurology

Nephrology

Others

By End-User

Biopharmaceuticals

Research Organisations

By Geography

North America

USA

Canada

Mexico

South America

Brazil

Argentina

Others

Europe

Germany

France

United Kingdom

Spain

Others

Middle East and Africa

Saudi Arabia

Israel

UAE

Others

Asia Pacific

China

Japan

South Korea

India

Others

Contents

1. INTRODUCTION

- 1.1. Market Definition
- 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

- 2.1. Research Data
- 2.2. Assumptions

3. EXECUTIVE SUMMARY

- 3.1. Research Highlights

4. MARKET DYNAMICS

- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porters Five Forces Analysis
 - 4.3.1. Bargaining Power of Suppliers
 - 4.3.2. Bargaining Power of Buyers
 - 4.3.3. Threat of New Entrants
 - 4.3.4. Threat of Substitutes
 - 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis

5. GLOBAL BIOBETTER MARKET ANALYSIS, BY TYPE

- 5.1. Introduction
- 5.2. Monoclonal Antibodies
- 5.3. Vaccines
- 5.4. Recombinant Proteins
- 5.5. Others

6. GLOBAL BIOBETTER MARKET ANALYSIS, BY APPLICATION

- 6.1. Introduction

- 6.2. Oncology
- 6.3. Neurology
- 6.4. Nephrology
- 6.5. Others

7. GLOBAL BIOBETTER MARKET ANALYSIS, BY END USER

- 7.1. Introduction
- 7.2. Biopharmaceuticals
- 7.3. Research Organisations

8. GLOBAL BIOBETTER MARKET ANALYSIS, BY GEOGRAPHY

- 8.1. Introduction
- 8.2. North America
 - 8.2.1. USA
 - 8.2.2. Canada
 - 8.2.3. Mexico
- 8.3. South America
 - 8.3.1. Brazil
 - 8.3.2. Argentina
 - 8.3.3. Others
- 8.4. Europe
 - 8.4.1. Germany
 - 8.4.2. France
 - 8.4.3. United Kingdom
 - 8.4.4. Spain
 - 8.4.5. Others
- 8.5. Middle East and Africa
 - 8.5.1. Saudi Arabia
 - 8.5.2. Israel
 - 8.5.3. UAE
 - 8.5.4. Others
- 8.6. Asia Pacific
 - 8.6.1. China
 - 8.6.2. Japan
 - 8.6.3. South Korea
 - 8.6.4. India
 - 8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

- 9.1. Major Players and Strategy Analysis
- 9.2. Emerging Players and Market Lucrativeness
- 9.3. Mergers, Acquisitions, Agreements, and Collaborations
- 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

- 10.1. Galil-Ofek
- 10.2. AstraZeneca
- 10.3. Compass Biotechnologies, Inc.
- 10.4. GC Pharma
- 10.5. Celltrion
- 10.6. Ildong Pharma

*list is not exhaustive

11. APPENDIX

I would like to order

Product name: Biobetter Market - Forecasts from 2019 to 2024

Product link: <https://marketpublishers.com/r/B5BD3EE26B6AEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B5BD3EE26B6AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970